Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eliquis
Pharma
BMS leans on long-term growth drivers to dodge IRA impacts
Facing pressure from the IRA and falling sales for Abecma, BMS CEO Chris Boerner says the Beyenzi-maker had a "good start" with the first quarter.
Zoey Becker
Apr 25, 2024 12:57pm
BMS CEO outlines transition strategy featuring 11 brands, BD
Feb 2, 2024 11:30am
ICER weighs in on Eliquis, Xarelto price negotiations at CMS
Oct 2, 2023 2:42pm
BMS aims for staggering 25 label expansions in the coming years
Sep 15, 2023 12:04pm
Amgen, J&J to see largest impact from IRA negotiations: Moody's
Sep 7, 2023 9:05am
CMS names 10 drugs up for first price negotiations under IRA
Aug 29, 2023 9:27am